


## PHARMACEUTICAL 2023

## BIOXYTRAN INC Rank 432 of 446





## PHARMACEUTICAL 2023

## BIOXYTRAN INC Rank 432 of 446

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 187% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 244% points.

The company's Economic Capital Ratio, given in the ranking table, is -412%, being 456% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	295
Cost of Goods Sold	0
Intangible Assets	76
Liabilities, Current	3,663
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	223
Other Liabilities	0
Other Net Income	-523
Other Revenues	0
Property and Equipment	0
Research and Development	978
Selling, General and Administrative Expense	934

Output Variable	Value in 1000 USD
Assets	371
Liabilities	3,663
Expenses	2,134
Revenues	0
Stockholders Equity	-3,293
Net Income	-2,657
Comprehensive Net Income	-2,657
Economic Capital Ratio	-412%

